June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Effect of Statins and Diabetes Therapy (Oral Hypoglycemics and Insulin) on the Outcomes of Patients Treated with Ranibizumab and/or Laser Therapy
Author Affiliations & Notes
  • Mohammad Sadiq
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
  • Muhammad Hassan
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
  • Yasir Sepah
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
  • Graeme Loh
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
    Division of medicine, University College London Medical School, London, United Kingdom
  • Saleema Kherani
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
  • Mostafa Hanout
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
  • Rachel Annam
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
  • Mehreen Ansari
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
  • Diana Do
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
  • Quan Dong Nguyen
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute. Johns Hopkins University, Baltimore, MD
  • Footnotes
    Commercial Relationships Mohammad Sadiq, None; Muhammad Hassan, None; Yasir Sepah, None; Graeme Loh, None; Saleema Kherani, None; Mostafa Hanout, None; Rachel Annam, None; Mehreen Ansari, None; Diana Do, Genentech (F), Regeneron (F); Quan Dong Nguyen, Genentech (F), Regeneron (F), Lux Biosciences (F), Abbott (F), GSK (F), Santen (F), Santen (C), Bausch and Lomb (C), Optos (F), Heidelberg Engineering (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4027. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mohammad Sadiq, Muhammad Hassan, Yasir Sepah, Graeme Loh, Saleema Kherani, Mostafa Hanout, Rachel Annam, Mehreen Ansari, Diana Do, Quan Dong Nguyen, ; Effect of Statins and Diabetes Therapy (Oral Hypoglycemics and Insulin) on the Outcomes of Patients Treated with Ranibizumab and/or Laser Therapy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4027.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the role of concomitant use of statins, oral hypoglycemics or insulin, and the status of diabetic retinopathy, in determining the outcomes of patients with diabetic macular edema (DME) who were treated either with laser, ranibizumab (RBZ), or a combination of RBZ and laser.

 
Methods
 

Data from the READ-2 study was utilized for this study. For the purpose of analysis, data from the three study groups was combined and then stratified based on the severity of diabetic retinopathy (DR) and the use of statins, oral hypoglycemics, or insulin. Baseline characteristics were analyzed for each subgroup. The outcome variables assessed were mean change in BCVA (ETDRS scores) and foveal thickness. The effect of each parameter on the outcome variables was assessed using the Mann-Whitney U test. The number of RBZ injections given after month 6 (based on retreatment criteria) was also compared between patients receiving oral hypoglycemics and insulin therapy.

 
Results
 

Baseline characteristics (age, race, gender, weight and hypertension) were found to be similar across all subgroups. No significant association was seen between the use of statins, insulin, or oral hypoglycemic agents on the outcome variables: foveal thickness and BCVA at month 6, 24, or 36 (P-values are shown in table 1). The severity of DR was also not associated with a significant change in the outcome. Mean number of injections required after month 6 were 5.51, 7.68, and 6.90 for patients on oral hypoglycemics alone, insulin alone, or a combination of both, respectively (p>0.05).

 
Conclusions
 

No significant association was detected between the use of concomitant medications such as statins, oral hypoglycemics, or insulin with the outcome of DME patients treated with RBZ, laser, or combination. Grade of DR was also not significantly associated with the outcome. Therefore, severity of DR and presence of co-morbidities should not affect treatment decisions for DME, as comparable visual benefits can still be achieved.

 
 
Table: Effect of Statins, Oral Hypoglycemics, Insulin and Severity of NPDR on outcome variables at month 6, 24 and 36
 
Table: Effect of Statins, Oral Hypoglycemics, Insulin and Severity of NPDR on outcome variables at month 6, 24 and 36
 
Keywords: 505 edema • 503 drug toxicity/drug effects • 498 diabetes  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×